Tumors develop on nerve tissue as a result of a series of hereditary diseases called neurofibromatoses. Anywhere in the neurological system, including the brain, spinal cord, and nerves, these tumors can form. Neurofibromatosis comes in three different forms: schwannomatosis, neurofibromatosis 1 (NF1), and neurofibromatosis 2 (NF2).
While NF2 and schwannomatosis are typically detected in early adulthood, NF1 is typically diagnosed in childhood. The tumors in these illnesses are often benign (noncancerous), but they occasionally develop into malignancy (malignant). Symptoms are frequently minor.
However, neurofibromatosis consequences can also result in hearing loss, learning disabilities, cardiovascular issues, vision loss, and excruciating pain. The goal of neurofibromatosis treatment is to promote healthy growth and development in affected children as well as the early detection and treatment of problems.
Surgery can lessen symptoms when neurofibromatosis results in big tumors or tumors that press against a nerve. Other treatments, such as stereotactic radiosurgery or painkillers, may be advantageous for some patients. Children’s tumors can now be treated with a brand-new drug, and other innovative therapies are being created. Most victims of this unusual form of neurofibromatosis are over the age of 20.
Ages 25 to 30 are the typical onset years for symptoms. On the cranial, spinal, and peripheral nerves, tumors can form as a result of schwannomatosis; however, this seldom happens on the nerve that transmits sound and balance data from the inner ear to the brain. Persons with schwannomatosis do not typically experience the same hearing loss as people with NF Type 2 because tumors do not typically develop on both hearing nerves.